You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Details for Patent: 7,067,555


✉ Email this page to a colleague

« Back to Dashboard


Title:Sertraline oral concentrate
Abstract: The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The present invention also provides a use of this concentrate composition to prepare an aqueous solution of sertraline. In addition, the present invention provides a method of using this concentrate composition to treat or prevent a variety of diseases or conditions. Finally, the present invention provides the compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalena- mine methanesulfonate.
Inventor(s): Harper; Nancy J. (Groton, CT), Ranade; Gautam R. (East Lyme, CT), Welch; Willard M. (Mystic, CT)
Assignee: Pfizer Inc (New York, NY)
Filing Date:Feb 03, 2004
Application Number:10/771,985
Claims:1. A pharmaceutical composition which comprises: an essentially nonaqueous, liquid concentrate solution for oral administration comprising an amount of sertraline or a pharmaceutically acceptable salt thereof and one or more essentially nonaqueous pharmaceutically acceptable excipients; wherein at least one of the excipients is liquid, and wherein the excipients are selected from the group consisting of ethanol, glycerin, polyethylene glycol and propylene glycols, and wherein the concentrate comprises sertraline in an amount of about 1 to about 88 mg/ml.

2. The composition of claim 1 wherein the pharmaceutically acceptable salt of sertraline is the hydrochloride salt or the mesylate salt.

3. The composition of claim 1 wherein the excipients are ethanol and glycerin.

4. The composition of claim 1 wherein the concentrate comprises sertraline hydrochloride in an amount of about 15 to about 30 mg/ml and wherein the excipients are ethanol and glycerin in an amount of about 8 to about 20% ethanol (by weight) in glycerin.

5. The composition of claim 4 wherein the concentrate further comprises one or more flavoring agents and one or more pharmaceutically acceptable preservatives.

6. The composition of claim 5 wherein the flavoring agents are selected from the group consisting of peppermint, spearmint and menthol; and wherein the preservatives are selected from the group consisting of butylhydroxytoluene, butylated hydroxyanisole, propyl gallate, ascorbic acid, ascorbyl palmitate, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, sodium hydroxide, cysteine, ethylenediamine tetraacetic acid or salts thereof, citric add, triethanolamine, thioglycerol, methylparaben and propylparaben.

7. The composition of claim 6 wherein the flavoring agent is menthol and wherein the preservative is butylhydroxytoluene.

8. The composition of claim 7 wherein each ml of the concentrate comprises about 22.4 mg of sertraline hydrochloride, about 151 mg of ethanol, about 0.50 mg of menthol, about 0.10mg of butylhydroxytoluene, and about 1011 mg of glycerin.

9. The compound, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalena- mine methanesulfonate.

10. A method of preparing an aqueous solution of sertraline comprising diluting an essentially nonaqueous, liquid concentrate of sertraline according to claim 1, or a pharmaceutically acceptable salt thereof, in an aqueous diluent prior to oral administration, said concentrate comprising an amount of sertraline or a pharmaceutically acceptable salt thereof and one or more essentially nonaqueous pharmaceutically acceptable excipients, wherein at least one of the excipients is liquid, and wherein the excipients are selected from the group consisting of ethanol, glycerin, polyethylene glycol and propylene glycols, and wherein the concentrate comprises sertraline in an amount of about 1 to about 88 mg/ml.

11. The method of claim 10, wherein the pharmaceutically acceptable salt of sertraline is the hydrochloride salt or the mesylate salt.

12. The method of claim 11 wherein the diluent is selected from the group consisting of water, orange juice, ginger ale, lemon-lime soda and lemonade.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.